FluoGuide A/S (FRA:96X)

Market Cap	64.29M +43.2%
Revenue (ttm)	29.46K -42.9%
Net Income	-5.28M
EPS	-0.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	3.670
Previous Close	3.650
Day's Range	3.670 - 3.710
52-Week Range	2.550 - 3.990
Beta	n/a
RSI	60.03
Earnings Date	May 27, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2018
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 96X

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK